Precision medicine has emerged as a transformative approach in cancer treatment, moving away from the traditional one-size-fits-all methodology toward highly individualized therapeutic strategies. This paradigm shift recognizes that each patient's cancer is unique, with distinct genetic profiles, molecular characteristics, and treatment responses that require tailored approaches. By leveraging advanced genomic technologies, biomarker identification, and sophisticated…
Shots:
The P-III (DeLLphi-304) trial evaluated Imdelltra (tarlatamab-dlle) vs SoC CT (topotecan globally excl. Japan; lurbinectedin in the US, Canada, Australia, Singapore, Korea; amrubicin in Japan) in SCLC pts (n=509) who progressed on or after 1L of Pt-based CT
Trial met its 1EP of superior OS & 2EPs of improved PFS & PROs for dyspnea…
Shots:
Amgen has reported P-III (DeLLphi-304) trial data evaluating Imdelltra (tarlatamab-dlle) vs SoC CT (topotecan globally excl. Japan; lurbinectedin in the US, Canada, Australia, Singapore, Korea; & amrubicin in Japan) in SCLC pts who progressed on or after single line of Pt-based CT
In the interim analysis, trial met its 1EP, with superior OS; full…
Shots:
Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers
Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma
The study reveals that four out of the ten patients received only…
Shots:
Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells
Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors
While highlighting the intellectual…
Shots:
Jeff spoke about IND acceptance by the US FDA for its lead flu drug-Fc conjugate immunotherapy for the prevention and treatment of Influenza
He also discussed Cidara’s collaboration with Janssen Pharmaceuticals to develop and commercialize Cidara’s DFCs
The interview also emphasizes Cidara’s Cloudbreak platform to develop immunotherapeutic antivirals and treatment options for influenza
Smriti:…

